Recent thymic emigrants (RTEs) CD4+
represent naive T-cells recently migrated from the thymus and are measured as a percent of CD4+
T-cells. A decrease or absence of RTEs is associated with a decrease or loss of thymic output in children, as seen in severe combined immunodeficiency (SCID), DiGeorge syndrome and other cellular immune deficiency disorders. RTE results should be interpreted with caution in adults due to age-related decline in thymic function. RTE assessment may also be used to evaluate immune reconstitution after hematopoietic cell transplant, post chemotherapy and in HIV patients undergoing highly active antiviral therapy (HAART). Serial measurement is recommended.
See Compliance Statement A
Statement A: Analyte specific reagents (ASR) are used in many laboratory tests necessary for standard medical care and generally do not require U.S. Food and Drug Administration (FDA) approval or clearance. This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. This test should not be regarded as investigational or for research use.